



**Experiences surrounding the diagnostic process and care  
among parents of children diagnosed with Phelan-Mcdermid  
Syndrome: A qualitative study in Spain.**

Journal:	<i>Developmental Medicine &amp; Child Neurology</i>
Manuscript ID	Draft
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	García-Bravo, Cristina; Universidad Rey Juan Carlos - Campus de Alcorcon, Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation Martínez-Piédrola, Rosa M; Universidad Rey Juan Carlos - Campus de Alcorcon, Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation García-Bravo, Sara; Physiocare Madrid, Physiotherapy Clinic. Huertas-Hoyas, Elisabet; Universidad Rey Juan Carlos - Campus de Alcorcon, Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation Pérez-de-Heredia-Torres, Marta; Universidad Rey Juan Carlos - Campus de Alcorcon, Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation Palacios-Ceña, Domingo; Universidad Rey Juan Carlos - Campus de Alcorcon, Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation
Keywords:	Phelan-Mcdermid Syndrome, Telomeric 22q13 Monosomy Syndrome, Rare Diseases, Parents, Qualitative research

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 1 **Experiences surrounding the diagnostic process and care among parents of**  
5 2 **children diagnosed with Phelan-Mcdermid Syndrome: A qualitative study in Spain**

6  
7 3 Running title: Parents and Phelan-Mcdermid Syndrome  
8  
9 4

10 5 **Abstract**

11  
12  
13 6 Aim

14  
15  
16 7 The Phelan-Mcdermid Syndrome (PMS) is a rare, underdiagnosed disease with no cure. The purpose of  
17 8 this study was to explore the experience of parents with children diagnosed with Phelan-Mcdermid  
18 9 Syndrome, regarding the diagnostic process, treatment, and medical care.  
19  
20  
21

22 10 Method

23  
24  
25 11 A qualitative exploratory study was conducted. Participants were recruited using non-probabilistic  
26 12 purposeful sampling. In total, 32 parents with children with PMS were included. In-depth interviews and  
27 13 researchers' field notes were used. An inductive thematic analysis was performed.  
28  
29  
30

31 14 Results

32  
33  
34 15 Five themes emerged: "The diagnostic process" described the diagnostic process and how it is  
35 16 communicated to the parents; "Treatment and expectations" described the expectations and hopes built on  
36 17 future treatment; "Family planning" described how parents deal with genetic counseling, planning to have  
37 18 more children after the diagnosis of PMS; "The world of disability" describes the parents' entry into the  
38 19 environment of dependency and disability after the diagnosis; "The family economy" showed the economic  
39 20 difficulties due to the high cost of therapies and daily care products.  
40  
41  
42  
43  
44  
45

46 21 Interpretation

47  
48  
49 22 Our results provide insight on how the diagnosis and their consequences are experienced by parents with  
50 23 children with PMD. These results can be used by health professionals to help and support parents.  
51  
52

53 24 Keywords (MeSH): Phelan-Mcdermid Syndrome; Telomeric 22q13 Monosomy Syndrome; Rare Diseases;  
54 25 Parents; Qualitative research  
55  
56  
57  
58  
59  
60

1  
2  
3 **27 List of Abbreviations in alphabetical order**  
4

5 28

6 29 ASD: Autism Spectrum Disorder  
7

8  
9 30 CGH: Comparative genomic hybridization  
10

11 31 DICE-APER: Primary Care for Rare Diseases  
12

13 32 FISH: Fluorescence in situ hybridization  
14

15 33 PMDS: Phelan-McDermid syndrome  
16

17 34 RD: Rare diseases  
18  
19  
20  
21

22 35  
23  
24

25 **36 What this paper adds**  
26  
27

- 28 37 • The Phelan-Mcdermid Syndrome breaks parents' expectations regarding diagnoses  
29 38 • Parents experience diagnoses process and its communication as different process  
30 39 • Disability and dependence appear abruptly in the parents' life.  
31 40 • Financial costs impact on family's structure and planification.  
32  
33  
34  
35

36 41  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1. Aim

Phelan-McDermid syndrome (PMDS), or 22q13.3 deletion, consists of a genetic mutation of the SHANK3 gene. This chromosomal abnormality is of autosomal dominant inheritance or appears spontaneously ("de novo")<sup>1,2</sup>. Due to the great phenotypic variety, PMD is an underdiagnosed syndrome<sup>3</sup>. The differential diagnosis of PMDS includes Prader-Willi, Fragile X, Angelman, Smith-Magenis, trichorhinophalangeal and velocardiofacial syndromes, Autism Spectrum Disorder (ASD), cerebral palsy, developmental delays and syndromes associated with hypotonia<sup>1,2,4</sup>. Upon confirmation of the genetic diagnosis, parents are recommended to receive genetic counseling<sup>5</sup>. Genetic counseling involves education sessions and multiple genetic testing to determine inheritance, understand diagnosis, and the progression of PMDS<sup>4</sup>. In rare diseases (RD), parents highlight how the diagnosis causes a strong emotional impact<sup>6,7</sup>.

At present, there is no specific pharmacological treatment for PMDS<sup>8</sup>. Most treatments are aimed at treating comorbidities such as anxiety, hyperactivity, and impulsive behaviors<sup>9</sup>. Due to the variability of the PMDS phenotype, shankopathies may present with neurodevelopmental impairment, neonatal hypotonia, intellectual disability, and/or ASD-like symptoms. Other neuropsychiatric manifestations include epilepsy, bipolar disorders, and schizophrenia<sup>10,11</sup>. PMDS is classified according to the involvement of the SHANK3 gene.

As with other pediatric-age rare diseases, parents have difficulty accessing medicines and public health services (diagnosis and therapies), having to bear the economic costs of private and specialized health care<sup>12,13</sup>. The experience of having children diagnosed with PMDS is highly individual, and qualitative research can provide a more holistic view that may be more meaningful to parents<sup>12</sup>. In contrast, there are no previous qualitative studies describing the experience of parents with children diagnosed with PMDS. The purpose of this study was to explore the experience of parents with children diagnosed with PMDS regarding the diagnostic process, treatment, medical care, and disability.

## 2. Method

### 2.1. Study design

A qualitative exploratory study was conducted<sup>14</sup>. This study was conducted according to the Standards for Reporting Qualitative Research<sup>15</sup>. Ethical approval for this study was granted by the Local Ethical Committee of Universidad X (code: 0810202017820). All participants provided oral informed

1  
2  
3 70 consent prior to their inclusion<sup>14</sup>. Six researchers (one man) participated in this study, including one  
4  
5 71 research nurse (DPC), one physical therapist (SGB) and four occupational therapists. All researchers had  
6  
7 72 experience in research in health sciences.  
8

## 9 73 **2.2. Participants, and sampling strategies**

10  
11  
12 74 The study included parents with Children diagnosed with PMDS by a medical specialist<sup>16</sup> and who  
13  
14 75 were attending the Asociación Síndrome Phelan McDermid (<https://22q13.org.es/>), Spain. The inclusion  
15  
16 76 criteria were: a) Parents who, at the time of the study had children diagnosed with PMDS (with genetic  
17  
18 77 diagnosis), and/or legal guardian; b) the diagnosis of PMDS was made by the pediatrician and/or the  
19  
20 78 neurologist, c) children could present any variation of PMDS (deletion or mutation), and d) signing the  
21  
22 79 informed consent. Exclusion criteria: a) a diagnosis not confirmed by the pediatrician and/or neurologist,  
23  
24 80 and b) not signing the informed consent.  
25

26 81 Purposive sampling was used, based on relevance to the research question (not clinical  
27  
28 82 representativeness)<sup>14</sup>. In the current study, the sample size was determined following the Turner-Bowker  
29  
30 83 et al proposal<sup>17</sup>. These authors<sup>17</sup> reported that 99.3% of concepts, themes, and contents emerged with around  
31  
32 84 30 interviews. With this proposal, a greater capacity to identify codes, categories, and topics is achieved.  
33  
34 85 In addition, the current proposal also helps researchers to know when to stop data collection and participant  
35  
36 86 recruitment.  
37

## 38 87 **2.3. Data collection**

39  
40  
41 88 Data were collected over a four-month period between November 2020 and February 2021. A  
42  
43 89 semi-structured question guide was used (**Table 1**). In addition, researcher field notes were kept during the  
44  
45 90 interviews<sup>18</sup>. During the interviews, researchers used prompts to encourage the participant to provide further  
46  
47 91 details.  
48

49  
50 92 Due to the lockdown situation established by the Spanish Government in response to the COVID-  
51  
52 93 19 pandemic<sup>19</sup>, interviews were conducted via a private video chat room using the Microsoft Teams  
53  
54 94 platform (<https://www.microsoft.com/es-es/microsoft-teams/log-in>). Each participant received a private  
55  
56 95 and personalized email with an invitation. All interviews were conducted by three authors (CGB, RMMP  
57  
58 96 and DPC). With participant oral permission, all interviews (n= 32) were audio- and video-recorded,  
59  
60 97 recording a total of 3,205 min of interviews overall (average of 100.16 ± 18.2 min each interview).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

98 Additionally, 32 field notes were collected by the researchers during the semi-structured interviews, since  
99 field notes provide a rich source of information<sup>18</sup>.

## 100 **2.4. Data analysis**

101 An inductive thematic analysis was performed<sup>14</sup>. The analysis consisted of identifying the most  
102 descriptive content in order to obtain codes, and subsequently reduce and identify the most common  
103 meaningful groups (categories). In this manner, groups of meaningful units were formed (i.e., similar points  
104 or content that allowed the emergence of the topics that described the study participants' experience)<sup>14,18</sup>.  
105 This process was performed separately on the interviews and the researchers' field notes. Also, double, and  
106 independent coding was performed by two investigators (CGB, DPC). After they then met to discuss,  
107 compare, and for a round of refinement. Subsequently, joint meetings were held to combine the results of  
108 the analysis, to represent the parents' experiences<sup>14,18</sup>. The Excel program was used to organize and share  
109 the coding process.

## 110 **2.5. Rigor**

111 The techniques performed to control trustworthiness are described in **Table 2**<sup>14,20</sup>.

## 112 **3. Results**

113 Thirty-two parents were recruited (23 women). The mean age of parents was 43 years and 4 months  
114 (SD  $\pm$ 6.85). The mean age of children with PMDS was 11 years and 7 months (SD  $\pm$ 9.79) and the age at  
115 the children's diagnosis was 7 years and 1 months (SD  $\pm$  10.04). The clinical and demographic features of  
116 participants are shown in **Table 3**.

117 Five specific themes emerged: a) The diagnostic process; b) Treatment and expectations; c) Family  
118 planning; d) The world of disability; and e) Family economy. We included some of the parents' narratives  
119 taken directly from the interviews in relation to the emerging themes (See **Supplementary file 1**).

### 120 **Theme 1: The diagnostic process**

121 The parents described the diagnostic process as a search. In that search they felt alone and that a  
122 lot of time is lost. Time that is essential for their children's treatment. In addition, they described a constant  
123 struggle to get the public health system to request specific genetic tests for diagnosis:

1  
2  
3 124 *"They requested it [the test], but as always, it was a streggle. We don't ask for much, it's for his*  
4  
5 125 *health and when you claim or ask for more specific tests for your child, they keep closing the door on you."*  
6  
7 126 (P27).

8  
9 127 Our participating mothers pointed out how their criteria or assessments of their child and his  
10  
11 128 development were questioned, causing them very unpleasant moments. Some parents highlighted the  
12  
13 129 moment when they were informed of the diagnosis as the most shocking news of their lives. They were so  
14  
15 130 "shocked" that they stopped listening, unable to hear anything else.

16  
17  
18 131 *"The day of the diagnosis was the worst day of my life, hands down. I've never been closer to*  
19  
20 132 *insanity ever, feeling like my brain was going to go ploff [popping gesture]." (P9).*

21  
22 133 However, other parents were relieved by the diagnosis because they found an explanation for their  
23  
24 134 children's behavior.

25  
26  
27 135 *"I felt relief. It upsets you, and it hurts, but it helped because after a long wait, we finally had an*  
28  
29 136 *answer." (P11).*

30  
31 137 Most of the parents described how the communication of the diagnosis by the health professional  
32  
33 138 was devastating, due to lack of training and knowledge of PMDS.

34  
35  
36 139 *"It's unacceptable that the person who is giving you the diagnosis doesn't even know what it is...it's*  
37  
38 140 *devastating." (P23).*

39  
40 141 **Theme 2: Treatment and your expectations**

41  
42  
43 142 Parents described how, in the absence of specific pharmacological treatment, therapies such as  
44  
45 143 physiotherapy, occupational therapy or speech therapy are their only tool and hope to fight PMDS. The  
46  
47 144 participants described how these therapies should be carried out by trained professionals, because no matter  
48  
49 145 how much the professionals teach parents to perform certain techniques at home, they perceive a clear  
50  
51 146 difference when the children go to a professional center.

52  
53 147 *"I talk to other parents, and they tell me that they have learned to become therapists and physical*  
54  
55 148 *therapists, but it's not true. We can't get so much out of the kids as they do. Taking her to therapy is the*  
56  
57 149 *most important thing I can do for her." (P23).*

1  
2  
3 150 A moment of great uncertainty and complexity for parents is to assess when a medication or  
4  
5 151 therapy is causing harm to their children and to decide when to stop.

6  
7 152 *"... there comes a time when you ask yourself, what are we waiting for to keep taking this*  
8  
9 153 *medication? Because you start to see other alterations that force you to rethink everything again, and you*  
10  
11 154 *may harm your daughter."* (P3).

12  
13  
14 155 Finally, all study participants emphasized that they had no hope for future treatment due to the  
15  
16 156 genetic complexity of the study.

17  
18 157 *"It is very sad, but we have no hope. We aren't going to fool ourselves; our son isn't going to get*  
19  
20 158 *better. We are aware that regression will come, we don't know when, but it will come. There is no hope at*  
21  
22 159 *all."* (P1).

### 23 24 25 160 **Theme 3: Family planning**

26  
27 161 This theme describes how parents consider having another child after the diagnosis of PMDS by  
28  
29 162 seeking genetic counseling, together with the couple's disagreements on the subject and the feeling of guilt  
30  
31 163 that sometimes ensues.

32  
33  
34 164 The decision to have another child is accompanied by great uncertainty and fear among couples.  
35  
36 165 After the diagnosis of PMDS, some participants considered genetic counseling as a tool to consider having  
37  
38 166 children again. Moreover, they recounted how receiving genetic counseling should always be accompanied  
39  
40 167 by psychological support, as it is a stressful and distressing situation.

41  
42 168 *"We went to genetic counseling, and they tried to convince me that the probability of having a*  
43  
44 169 *child with the syndrome again was very low... but don't talk to me about probability because I have had a*  
45  
46 170 *child Phelan McDermid Syndrome. Not everything is statistics... Besides, where is the mental health*  
47  
48 171 *service? We were never given that."* (P9).

49  
50 172 For some couples, considering a new pregnancy is an opportunity to recover all those experiences  
51  
52 173 that they have not been able to live, and to have a more complete experience of motherhood/parenthood.  
53  
54 174 Meanwhile, for other participants, the decision for another pregnancy caused conflicts between the couple.  
55  
56 175 Some of the participants reported that they felt guilty about deciding to have another child, because taking  
57  
58 176 care of the sibling with PMDS could be a burden for their sibling in the future.



1  
2  
3 **177 Theme 4: The world of disability**  
4

5  
6 178 The parents interviewed described how they are immersed in a world they never knew existed and  
7  
8 179 had never been interested in. All our parents pointed out that no one has prepared them to accept that their  
9  
10 180 children "have a disability" and are labeled as "disabled".

11  
12 181 *"It's hard to have a child and acknowledge that they are a person with a disability...because you've*  
13  
14 182 *already put the label on them, a disabled person...I felt a huge grief..." (P24).*

15  
16 183 Paradoxically, parents described how they had to use "identifiers" on their clothes to highlight that  
17  
18 184 their child had a disability and to be able to tolerate the child's behavior on the street. This type of marking  
19  
20 185 was used during the confinement period of the COVID-19 pandemic, where only children with special or  
21  
22 186 health conditions were allowed to go out on the street.

23  
24  
25 187 *"We had to put a blue armband on them so we wouldn't have problems with people. To have them*  
26  
27 188 *marked with a bracelet as if they were animals so that people would understand. People aren't prepared*  
28  
29 189 *to understand disability, much less our children who are not physically noticeable." (P8).*

30  
31 190 Some parents described how the assessment of disability by public agencies is erratic, takes a long  
32  
33 191 time, and the staff that performs it is unqualified and do not know what PMDS is.

34  
35  
36 **192 Theme 5: The family economy**  
37

38  
39 193 Parents must make a considerable financial effort to cover the daily care needs of their children  
40  
41 194 (adapted car and wheelchair, diapers) with PMDS. Another problem reported was the difficulty of  
42  
43 195 combining work schedules with the schedules of therapies and medical appointments for their children.  
44  
45 196 This situation is intensified when both parents work to obtain financial resources to meet all the costs of  
46  
47 197 therapy and daily care.

48  
49 198 *"On a work level it is complex having to combine all the schedules, but you can't stop working*  
50  
51 199 *because you have to pay for a lot of things." (P11).*

52  
53 200 Eventually, one of the parents must give up work, due to the high demands of caring for a child  
54  
55 201 with PMDS. In our study, it was common for the mother to reduce her working hours or quit her job.

56  
57  
58 **202 4. Discussion**  
59  
60

1  
2  
3 203 This study has highlighted the experiences of parents of children with PMDS. Overall, they  
4  
5 204 experience a difficult and lengthy diagnostic process, waking up in the world of disability with the shock  
6  
7 205 that this entails, which comes with a high financial burden. In addition, the parents spoke of the need to  
8  
9 206 incorporate multiple non-pharmacological therapies to help their children and one of the issues that was  
10  
11 207 emphasized was the need to seek genetic counseling should they decide to have another child.  
12

13 208 Previous studies in RD describe the diagnosis as a long process, where many professionals have  
14  
15 209 poor knowledge of the disease, making it difficult to request appropriate tests<sup>6,21,22</sup>. Ivarsson et al.<sup>6</sup> described  
16  
17 210 how parents must continually complain to get a diagnosis. Participants in the present study noted the  
18  
19 211 constant struggle to get the diagnostic tests that would serve to identify PMDS. Moreover, our participants  
20  
21 212 described the anguish and uncertainty they felt in finding the cause of the disease to be able to give "a  
22  
23 213 name" to what was happening to their child. In agreement with our results, several studies describe the  
24  
25 214 "journey from doubt and hope to diagnosis" experienced by parents of children with RD, which helps them  
26  
27 215 to find explanations for their child's behaviors<sup>6,23,24</sup>. During the search for a diagnosis, children with PMDS,  
28  
29 216 previously go through several diagnoses. Previous studies show that children with RD receive several  
30  
31 217 diagnoses before reaching a definitive diagnosis, which is often delayed in time<sup>21,23</sup>.  
32

33 218 The communication of the diagnosis by the health professional is a very delicate moment for the  
34  
35 219 parents. In our study, receiving the diagnosis from a professional who has no knowledge of the disease is a  
36  
37 220 devastating process. Previous studies describe the moment of communicating the diagnosis of RD to the  
38  
39 221 parents as a key element for understanding and coping with the disease, as well as for psychological well-  
40  
41 222 being and proactive participation in the different treatments<sup>7,25,26</sup>. In addition, they distinguish between poor  
42  
43 223 and effective communication, based on the involvement and interest of the health professional<sup>7,25,26</sup>.  
44

45 224 Currently, there is no pharmacological treatment for PMDS and medical treatments are aimed at  
46  
47 225 treating comorbidities<sup>8,9</sup>. The lack of treatment for RD derives in feelings of frustration and distress among  
48  
49 226 parents<sup>21</sup>. In addition, previous studies in RD highlight the difficulty parents have in adhering to treatments  
50  
51 227 that attempt to reduce symptoms<sup>21,27</sup>. Parents must decide which therapies and treatments to continue based  
52  
53 228 on the presence of benefits and harms (side effects) for their children<sup>21,27</sup>. In other studies, this decision is  
54  
55 229 influenced by disease status and progression<sup>27,28</sup>. SHANK3 gene involvement can lead to the development  
56  
57 230 of behavioral symptoms consistent with ASD. Recent studies affirm that ASD-targeted therapies, are a  
58  
59 231 good option for children with PMDS with SHANK3 involvement<sup>29</sup>. In addition, parents of children with  
60

1  
2  
3 232 RD rate therapies such as physiotherapy, occupational therapy and/or speech therapy as a fundamental pillar  
4  
5 233 in the daily struggle against disability and symptoms<sup>18,30</sup>.

6  
7 234 Genetic counseling is a multidisciplinary resource that includes diagnosis, information about the  
8  
9 235 disease, psychological support, and consultation about the possibilities of having a child with an anomaly  
10  
11 236 or other detectable genetic problem<sup>31</sup>. This would explain the importance given by parents to genetic  
12  
13 237 counseling when planning to have another child. However, along with genetic counseling, psychological  
14  
15 238 and emotional support for parents should be incorporated<sup>22-24</sup>.

16  
17  
18 239 Regarding having another child after the diagnosis of PMDS, our results coincide with previous  
19  
20 240 studies<sup>24,32</sup> where some parents wish to have another child after receiving the diagnosis, whereas others  
21  
22 241 choose to not have any more children because of the high daily care demands of the child with PMDS and  
23  
24 242 the associated financial burden.

25  
26 243 Haegele et al.<sup>32</sup>, in their study on children with chronic metabolic disease, describe how after the  
27  
28 244 diagnosis, parents experience moments of frustration and dread when they think that their child is  
29  
30 245 "different". Our participants also spoke of encountering and discovering the world of disability and the  
31  
32 246 impact they experienced when "labeling" their child as disabled. Along these lines, previous studies also  
33  
34 247 describe the psychological burden and difficulty of assimilating disability among parents of children with  
35  
36 248 RD<sup>32-34</sup>. This can be explained by the stigmatization and lack of understanding of their social environment,  
37  
38 249 including their own family<sup>32-34</sup>. For parents "being different" is a problem they face in their daily lives,  
39  
40 250 feeling judged and misunderstood by other adults<sup>32</sup>. Our participants also spoke of the feeling of  
41  
42 251 incomprehension of others towards their children's disability and disruptive behaviors.

43  
44 252 Our results show how parents assume a high financial burden to cover therapies and daily care. A  
45  
46 253 significant financial investment is common in children with RD, where families cover all expenses that are  
47  
48 254 not covered by insurance or public health care<sup>20,26</sup>. Orthopedic aids, autonomy devices and individualized  
49  
50 255 therapies are some of the most identified costs<sup>22,32</sup>. Paradoxically, in addition to these costs, the high burden  
51  
52 256 of care and childcare forces some parents to reduce their working hours or leave work to care for their  
53  
54 257 children, reducing their income<sup>22,33</sup>.

55  
56 258 **5. Conclusions**  
57  
58  
59  
60

1  
2  
3 259 Our results show how parents experience the diagnosis of PMDS and its impact on parents. These  
4  
5 260 results can be used by healthcare professionals to help and support parents during diagnosis and treatment  
6  
7 261 and/or therapy. There is a need to develop programs that integrate health and social interventions that help  
8  
9 262 parents of children with PMDS to care for and minimize the impact of the disease on the family.

10  
11 263 **Acknowledgements.**  
12

13  
14 264 The authors declare that no funds, grants, or other support were received during the preparation of this  
15  
16 265 manuscript. We thank the parents for their kind collaboration and participation in this research study, and  
17  
18 266 the Asociación Síndrome Phelan McDermid (<https://22q13.org.es/>) for their work and support.  
19

20 267 **Supporting information**  
21

22  
23  
24 268 Supplementary Material 1, reports some of the patients' narratives taken directly from the interviews and  
25  
26 269 personal letters regarding the emerging themes.

27  
28  
29 270 Supplementary Material 2, online table of contents of manuscript.  
30  
31  
32 271

272 **References**

- 273 [1] Droogmans G, Swillen A, Van Buggenhout G (2020) Deep Phenotyping of Development,  
274 Communication and Behaviour in Phelan-McDermid Syndrome. *Mol Syndromol*; 10(6):294-305.  
275 <https://doi.org/10.1159/000503840>
- 276 [2] Kavakli AS, Sugur T, Metinyurt HF (2020) Anaesthesia and orphan disease: Phelan- McDermid  
277 síndrome. *Eur J Anaesthesiol*; 37(8):730-731. <https://doi.org/10.1097/EJA.0000000000001242>
- 278 [3] Luo Y, Qian Y, Wang L, Yang Y, Sun Y, Jin F, et al. (2019) Prenatal diagnosis of a fetus with Phelan-  
279 McDermid syndrome. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. 2019; 36(8):841-843.  
280 <https://doi.org/10.3760/cma.j.issn.1003-9406.2019.08.022>.
- 281 [4] Richards C, Powis L, Moss J, Stinton C, Nelson L, Oliver C (2017) Prospective study of autism  
282 phenomenology and the behavioural phenotype of Phelan-McDermid syndrome: comparison to fragile X  
283 syndrome, Down syndrome and idiopathic autism spectrum disorder. *J Neurodev Disord*; 9(1):37.  
284 <https://doi.org/10.1186/s11689-017-9217-6>.
- 285 [5] Than NG, Papp Z (2017) Ethical issues in genetic counseling. *Best Pract Res Clin Obstet Gynaecol*;  
286 43:32-49. <https://doi.org/10.1016/j.bpobgyn.2017.01.005>.
- 287 [6] Ivarsson B, Johansson A, Kjellström B (2021) The Odyssey from Symptom to Diagnosis of Pulmonary  
288 Hypertension from the Patients and Spouses Perspective. *J Prim Care Community Health*;  
289 12:21501327211029241. <https://doi.org/10.1177/21501327211029241>
- 290 [7] Llubes-Arrià L, Sanromà-Ortíz M, Torné-Ruiz A, Carillo-Álvarez E, García-Expósito J, Roca J (2022)  
291 Emotional experience of the diagnostic process of a rare disease and the perception of support systems: A  
292 scoping review. *J Clin Nurs*; 31(1-2):20-31. <https://doi.org/10.1111/jocn.15922>.
- 293 [8] Verhoeven WMA, Egger JIM, de Leeuw N (2020) A longitudinal perspective on the pharmacotherapy  
294 of 24 adult patients with Phelan McDermid syndrome. *Eur J Med Genet*; 63(3):103751.  
295 <https://doi.org/10.1016/j.ejmg.2019.103751>.
- 296 [9] Dunn JT, Mroczek J, Patel HR, Ragozzino ME (2020) Tandospirone, a partial 5-HT1A receptor agonist,  
297 administered systemically or into anterior cingulate attenuates repetitive behaviors in Shank3B mice. *Int J*  
298 *Neuropsychopharmacol*; pyaa047. <https://doi.org/10.1093/ijnp/pyaa047>

- 1  
2  
3 299 [10] Alsufiani HM, Alkhanbashi AS, Laswad NAB, Bakhadher KK, Alghamdi SA, Tayeb HO, et al. (2022)  
4  
5 300 Zinc deficiency and supplementation in autism spectrum disorder and Phelan-McDermid syndrome. *J*  
6  
7 301 *Neurosci Res*. <https://doi.org/10.1002/jnr.25019>.
- 8  
9 302 [11] Phelan K, Boccuto L, Powell CM, Boeckers TM, van Ravenswaaij-Arts C, Rogers RC, et al. (2022)  
10  
11 303 Phelan-McDermid syndrome: a classification system after 30 years of experience. *Orphanet J Rare Dis*;  
12  
13 304 17(1):27. <https://doi.org/10.1186/s13023-022-02180-5>.
- 14  
15 305 [12] Pasquini TLS, Goff SL, Whitehill JM (2021) Navigating the U.S. health insurance landscape for  
16  
17 306 children with rare diseases: a qualitative study of parents' experiences. *Orphanet J Rare Dis*;16(1):313.  
18  
19 307 <https://doi.org/10.1186/s13023-021-01943-w>.
- 20  
21 308 [13] Güeita-Rodríguez J, Famoso-Pérez P, Salom-Moreno J, Carrasco-Garrido P, Pérez-Corrales J,  
22  
23 309 Palacios-Ceña D (2020) Challenges Affecting Access to Health and Social Care Resources and Time  
24  
25 310 Management among Parents of Children with Rett Syndrome: A Qualitative Case Study. *Int J Environ Res*  
26  
27 311 *Public Health*; 17(12):4466. <https://doi.org/10.3390/ijerph17124466>.
- 28  
29 312 [14] Creswell JW, Poth CN (2018) *Qualitative Inquiry and Research Design: Choosing among Five*  
30  
31 313 *Approaches*. 4th ed. Sage: Thousand Oaks.
- 32  
33 314 [15] O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA (2014) Standards for reporting qualitative  
34  
35 315 research: A synthesis of recommendations. *Acad Med*; 89(9):1245–1251.  
36  
37 316 <https://doi.org/10.1097/ACM.0000000000000388>.
- 38  
39 317 [16] Ministerio de Sanidad, Servicios Sociales e Igualdad (2014) Estrategia en Enfermedades Raras del  
40  
41 318 Sistema Nacional de Salud.  
42  
43 319 [https://www.sanidad.gob.es/organizacion/sns/planCalidadSNS/pdf/Estrategia\\_Enfermedades\\_Raras\\_SNS](https://www.sanidad.gob.es/organizacion/sns/planCalidadSNS/pdf/Estrategia_Enfermedades_Raras_SNS)  
44  
45 320 [\\_2014.pdf](https://www.sanidad.gob.es/organizacion/sns/planCalidadSNS/pdf/Estrategia_Enfermedades_Raras_SNS) Accessed on 03 February 2022
- 46  
47 321 [17] Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A, et al. (2018)  
48  
49 322 Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical  
50  
51 323 outcome assessment instrument development. *Value Health*; 21:839–842.  
52  
53 324 <https://doi.org/10.1016/j.jval.2017.11.014>.
- 54  
55 325 [18] Moser A, Korstjens I (2018) Series: Practical guidance to qualitative research. Part 3: Sampling, data  
56  
57 326 collection and analysis. *Eur. J. Gen. Pract*; 24:9–18. <https://doi.org/10.1080/13814788.2017.1375091>.

- 1  
2  
3 327 [19] Gobierno de España Real Decreto 463/2020, de 14 de Marzo, por el que se Declara el Estado de Alarma  
4  
5 328 para la Gestión de la Situación de Crisis Sanitaria Ocasionada por el COVID-19 (2020). Available online:  
6  
7 329 [https://www.boe.es/diario\\_boe/txt.php?id=BOE-A-2020-3692](https://www.boe.es/diario_boe/txt.php?id=BOE-A-2020-3692). Accessed on 10 November 2020.  
8  
9 330 [20] Korstjens I, Moser A (2018) Series: practical guidance to qualitative research. Part 4: Trustworthiness  
10  
11 331 and publishing. *Eur J Gen Pract*; 24:120–4. <https://doi.org/10.1080/13814788.2017.1375092>  
12  
13  
14 332 [21] Cheung M, Rylands AJ, Williams A, Bailey K, Bubbear J (2021) Patient-Reported Complications,  
15  
16 333 Symptoms, and Experiences of Living With X-Linked Hypophosphatemia Across the Life-Course. *J*  
17  
18 334 *Endocr Soc*; 23;5(8):bvab070. <https://doi.org/10.1210/jendso/bvab070>.  
19  
20 335 [22] Simpson A, Ross R, Porter J, Dixon S, Whitaker MJ, Hunter A J (2018) Adrenal Insufficiency in  
21  
22 336 Young Children: a Mixed Methods Study of Parents' Experiences. *Genet Couns*; 27(6):1447-1458.  
23  
24 337 <https://doi.org/10.1007/s10897-018-0278-9>  
25  
26  
27 338 [23] Palacios-Ceña D, Famoso-Pérez P, Salom-Moreno J, Carrasco-Garrido P, Pérez-Corrales J, Paras-  
28  
29 339 Bravo P, et al. (2018) "Living an Obstacle Course": A Qualitative Study Examining the Experiences of  
30  
31 340 Caregivers of Children with Rett Syndrome. *Int J Environ Res Public Health*; 25;16(1):41.  
32  
33 341 <https://doi.org/10.3390/ijerph16010041>  
34  
35 342 [24] Merker VL, Plotkin SR, Charns MP, Meterko M, Jordan JT, Elwy AR (2021) Effective provider-  
36  
37 343 patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with  
38  
39 344 schwannomatosis. *Patient Educ Couns*; 104(4):808-814. <https://doi.org/10.1016/j.pec.2020.09.029>.  
40  
41 345 [25] Germení E, Vallini I, Bianchetti MG, Schulz PJ (2018) Reconstructing normality following the  
42  
43 346 diagnosis of a childhood chronic disease: does "rare" make a difference? *Eur J Pediatr*; 177(4):489-495.  
44  
45 347 <https://doi.org/10.1007/s00431-017-3085-7>.  
46  
47  
48 348 [26] Goodspeed K, Bliss G, Linnehan D (2020) Bringing everyone to the table - findings from the 2018  
49  
50 349 Phelan-McDermid Syndrome Foundation International Conference. *Orphanet J Rare Dis*; 15(1):152.  
51  
52 350 <https://doi.org/10.1186/s13023-020-01389-6>  
53  
54 351 [27] Peay HL, Fischer R, Tzeng JP, Hesterlee SE, Morris C, Martin AS et al. (2019) Gene therapy as a  
55  
56 352 potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients  
57  
58 353 and parents. *PLoS One*. 2019 May 1;14(5):e0213649. <https://doi.org/10.1371/journal.pone.0213649>.  
59  
60

- 1  
2  
3 354 [28] Porter KA, O'Neill C, Drake E, Parker S, Escolar ML, Montgomery S, et al. (2021) Parent Experiences  
4  
5 355 of Sanfilippo Syndrome Impact and Unmet Treatment Needs: A Qualitative Assessment. *Neurol Ther*;  
6  
7 356 10(1):197-212. <https://doi.org/10.1007/s40120-020-00226-z>.
- 8  
9 357 [29] Ponson L, Gomot M, Blanc R, Barthelemy C, Roux S, Munnich A, et al. (2018) 22q13 deletion  
10  
11 358 syndrome: communication disorder or autism? Evidence from a specific clinical and neurophysiological  
12  
13 359 phenotype. *Transl Psychiatry*; 8;8(1):146. <https://doi.org/10.1038/s41398-018-0212-9>.
- 14  
15 360 [30] Sestini S, Paneghetti L, Lampe C, Betti G, Bond S, Bellettato CM, et al. (2021) Social and medical  
16  
17 361 needs of rare metabolic patients: results from a MetabERN survey. *Orphanet J Rare Dis*; 3;16(1):336. doi:  
18  
19 362 10.1186/s13023-021-01948-5.
- 20  
21 363 [31] Cacioppo CN, Chandler AE, Towne MC, Beggs AH, Holm IA (2016) Expectation versus Reality: The  
22  
23 364 Impact of Utility on Emotional Outcomes after Returning Individualized Genetic Research Results in  
24  
25 365 Pediatric Rare Disease Research, a Qualitative Interview Study. *PLoS One*; 15;11(4):e0153597.  
26  
27 366 <https://doi.org/10.1371/journal.pone.0153597>.
- 28  
29 367 [32] Haegele JA, Holland SK, Hill E (2022) Understanding Parents' Experiences with Children with Type  
30  
31 368 1 Diabetes: A Qualitative Inquiry. *Int J Environ Res Public Health*; 4;19(1):554.  
32  
33 369 <https://doi.org/10.3390/ijerph19010554>.
- 34  
35 370 [33] Uhlenbusch N, Löwe B, Depping MK (2019) Perceived burden in dealing with different rare diseases:  
36  
37 371 a qualitative focus group study. *BMJ Open*; 29;9(12):e033353. [https://doi.org/10.1136/bmjopen-2019-](https://doi.org/10.1136/bmjopen-2019-033353)  
38  
39 372 033353
- 40  
41 373 [34] Duma VV, Tshabalala N, Mji G (2021) The black hole of dealing with a disability diagnosis: Views  
42  
43 374 of South African rural parents. *Afr J Disabil*; 29;10:951. <https://doi.org/10.4102/ajod.v10i0.951>  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



375 **Table 1. Semi-structured question guide**

Areas of research	Questions
Disease	What is it like to live with Phelan McDermid Syndrome? What is most relevant for you? How does it affect your daily life? What are your expectations about the disease and its evolution?
Diagnosis	What was the process leading up to the diagnosis? What was the most relevant aspect of this process? How was the diagnosis communicated to you?
Treatment and care	<p>What treatment is your child currently receiving? What is most relevant to you? How does it affect or limit your daily life?</p> <p>Does it have any side effects? What are your treatment expectations?</p> <p>What barriers and facilitators do you think influence following through with the recommended treatment?</p> <p>Do you use any strategies to cope with the symptoms of the disease?</p> <p>How do you apply caregiving to your child? What barriers and/or facilitators do you have when caring for your child?</p>
Impact on parents	<p>How do you experience your child's illness? What is most relevant?</p> <p>How has it influenced the family's day-to-day organization and planning?</p> <p>At what times/situations have you needed to seek help? What type of help was it?</p>

376

377

378 **Table 2. Trustworthiness criteria.**

379

Criteria	Techniques Performed and Application Procedures
Credibility	<p data-bbox="507 376 1417 405">Investigator triangulation: each interview was analyzed by two researchers.</p> <p data-bbox="507 443 1417 544">Team meetings were performed in which the analyses were compared and categories and themes were identified.</p> <p data-bbox="507 577 1417 678">Triangulation of methods of data collection: semistructured interviews were conducted and researcher field notes were kept.</p> <p data-bbox="507 712 1417 947">Participant validation (member-checking): asking the participants to confirm the data obtained at the stages of data collection. All participants were offered the opportunity to review the audio and/or video records to confirm their experience. None of the participants made additional comments.</p>
Transferability	<p data-bbox="507 981 1417 1149">In-depth descriptions of the study performed, providing details of the characteristics of researchers, participants, contexts, sampling strategies, and the data collection and analysis procedures.</p>
Dependability	<p data-bbox="507 1182 1417 1485">Audit by an external researcher: an external researcher assessed the research protocol, focusing on aspects concerning the methods applied and study design. An external researcher specifically checked the description of the coding tree, the major themes, participants' quotations, quotations' identification, and themes' descriptions.</p>
Confirmability	<p data-bbox="507 1525 1417 1626">Investigator triangulation, member-checking, and data collection triangulation.</p> <p data-bbox="507 1659 1417 1760">Researcher reflexivity was encouraged via the performance of reflexive reports and by describing the rationale behind the study.</p>

380

381

382 **Table 3. Demographic and clinical features**

Participants	n=32
Sex	Male: 9 Female: 23
Age	Mean age: 43 years & 3.8 months SD: 6.85
Civil status	Married: 25 Divorced: 7
Number of children	Mean: 1,94 SD: 0,72
Age of children with PMS	Mean: 11 years & 6.6 months SD: 9.79
Child's age at diagnosis	Mean: 7 years & 0.4 months SD: 10.04
Diagnoses	Deletion: 30 SHANK3 gene mutation: 2

383

384

385

## Supplementary information

### Supplementary file 1. Narratives from Themes

---

#### Narratives from Theme: The diagnostic process

---

Search for the diagnosis:

*“And as parents, you are always saying: 'for sure, this test will be nothing and will remain an anecdote', and of course, you don't know that there are rare diseases or anything, it is a world that is totally distant from you until you get to know it.”* (P24).

*"You feel like everything is a waste of time. You feel alone because you go places and no one knows, no one understands, and no one wants to know. It wastes precious time for my son."* (P1).

Fighting for the diagnosis:

*“We insisted a lot to the pediatrician to send us to the neuropsychiatrist and after a lot of struggle, they sent us the tests. We talked about this and it took more than a year for the test to be carried out...”* (P2).

Feeling crazy:

*“The feeling I have is that they saw me as a crazy person... a crazy mother who saw things where there were none... it is a very unpleasant feeling...”* (P8).

*“They labeled me as being a very crazy mother. They doubted what I told them, what I saw in my son. They told me I was seeing ghosts, that I was imagining things.”* (P11).

Communication of the diagnosis:

*“They give you the biggest news of your life in the crappiest way. We left the office without knowing what I had. We were shocked”* (P25).

*“When they tell you the name you don't hear anything else, it's like they drop the bomb and then you just hear a ringing sound, like the one at the end of a movie. It doesn't matter what they tell you because you don't hear anything anymore.”* (P24).

Receiving the diagnosis:

*“Even though you know something is going on, you actually break down because you always have a hope that it's nothing. Naming it gave me a lot of peace, even though you are told that it's for life.”* (P14).

*"I felt relieved because I had been assuming it for a long time, I just wanted to be told clearly what it was."* (P11).

*“when you get the diagnosis you hear nothing but the name of the syndrome, no matter what they tell you.”* (P19).

Communication of the diagnosis by health care providers:

*"Imagine, my world came crashing down when I didn't even know what a neurologist was..."* (P20).

---

#### Narratives from Theme: Treatment and expectations

---

Therapy:

*"It's the only thing we can do as parents, take him to therapies. There are times when you think,*

1  
2  
3 *will you be giving him enough therapies, or too many... will they be adequate or would he need*  
4 *others instead..." (P2).*  
5

6 *"In the end, instead of taking him to soccer, you take him to therapies... you have to look at it*  
7 *like that." (P6).*  
8

9 **Importance of therapies:**

10 *"Therapies are basic. As much as we want to, we can't give him everything he needs, sometimes*  
11 *we don't have the energy or we don't know how to approach it. Parents, no matter how much*  
12 *we say we are all-inclusive, we have different approaches." (P24).*  
13

14 *"...having a daughter with such great difficulties makes you feel helpless. The only thing you*  
15 *can do is take her to other therapies because there is no pharmacological treatment..." (P9).*  
16

17 **Medication:**

18  
19 *"In the end you have to put everything in a balance. The benefits and what is bad for him due*  
20 *to the medication... if he doesn't die of his liver, he will die of something else... and at least he*  
21 *is better". (P32).*  
22

23 **Expectations for future treatment:**

24 *"They are doing tests and things, but to fix it they would have to change the proteins he has in*  
25 *his whole body, I have no hope for that. It seems very complicated to me and the thought of it*  
26 *makes me very anxious." (P14).*  
27

28  
29 **Narratives from Theme: Family planning**

30 **Genetic counseling:**

31 *"genetic counseling is essential to be able to have a child with certain guarantees and peace of*  
32 *mind." (P3).*  
33

34 *"the moment they call you to give you the results, it makes your heart sink." (P6).*  
35

36 **Thinking about having another child:**

37 *"we were a little scared, but it didn't have to go wrong this time." (P4).*  
38

39 *"We deserved to have a full parenting experience...enjoy ourselves in a way we hadn't with her."*  
40 *(P17).*  
41

42 **Disagreements:**

43 *"We had a conflict as a couple because I would have liked to have another child. Besides, I*  
44 *thought it was beneficial for her, but my husband saw it as stealing time from her, stealing*  
45 *dedication from her and...and no." (P3).*  
46

47 *"We went through a complicated period because I wanted another child, I thought it would help*  
48 *us in this madness, but my wife didn't want it and I didn't understand it." (P30).*  
49

50  
51  
52 **Feeling guilty:**

53 *"You get to feel guilty when she thinks about it because he's a child who could have a better life*  
54 *and he's already conditioned. In the future, he's going to be a burden on his sister." (P31).*  
55  
56

57 **Narratives from Theme: The World of Disability**

58  
59 **Being unprepared:**  
60

1  
2  
3 *"It's something they never prepare you for. And when the diagnosis comes, your world falls*  
4 *apart."* (P22).

5  
6 Entering the world of disability:

7 *"Suddenly, you find yourself in a world that you didn't know existed, you didn't know there*  
8 *were rare diseases or anything else and you didn't think about being part of it... it's a very big*  
9 *blow."* (P28).

10  
11 *"Suddenly you're in a parallel world that you hadn't stopped to look at and you don't discover*  
12 *it until you're inside."* (P20).

13  
14 People don't understand disability:

15  
16 *"...everyone knows so much and tells you how you have to do it and...then, you spend all day*  
17 *crying because everyone thinks they know and they don't have a clue..."* (P5).

18  
19 Disability assessment:

20  
21 *"The disability assessment process is cumbersome because you have to go there a thousand*  
22 *times, to be assessed... when they know that it's a rare disease, which unfortunately for us, is*  
23 *not going to improve, and if it does, it will only improve slightly..."* (P6).

24  
25 **Narratives from Theme: The family economy**

26  
27 Financial effort:

28 *"These children have a lot of expenses. Therapies, diapers, wheelchairs... and all of this is*  
29 *private because there is almost no help."* (P14).

30  
31 *"My son had a very strong regression and I had to quit my job, because I couldn't take care*  
32 *of him, take him to therapies and work. He needed me so much that I had to quit my job..."*  
33 *(P8).*

34  
35 *"Diana needs an adapted car that costs 3000€ to adapt. How does a family cope with that?*  
36 *It's a total ruin. And there are more expenses like diapers, which are daily."* (P9).

37  
38 The need to work:

39 *"...we can't afford a reduction in the working day because we have to keep up with all his*  
40 *therapies, aids, pills..."* (P4).

41  
42 Having to stop working:

43 *"When I was working, it was like drowning and, in the end, you look at the benefit and it's*  
44 *not that much. We decided to give up other things and be more comfortable taking care of*  
45 *the child".* (P14).

## *Developmental Medicine & Child Neurology*

The present manuscript “*Experiences surrounding the diagnostic process and care among parents of children diagnosed with Phelan-Mcdermid Syndrome: A qualitative study in Spain.*” was conducted following the Standards for Reporting Qualitative Research-SRQR (<https://www.equator-network.org/>).

Check list from **Standards for Reporting Qualitative Research (SRQR): 21-item checklist.**

Reference: O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. *Acad Med.* 2014;89(9):1245-1251.

No	Item	Guide questions/description	Yes/no
	<b>Title and abstract</b>		
S1	Title	Concise description of the nature and topic of the study Identifying the study as qualitative or indicating the approach (e.g., ethnography, grounded theory) or data collection methods (e.g., interview, focus group) is recommended	Yes, page 1
S2	Abstract	Summary of key elements of the study using the abstract format of the intended publication; typically includes background, purpose, methods, results, and conclusions	Yes, page 1-2
	<b>Background</b>		
S3	Problem formulation	Description and significance of the problem/phenomenon studied; review of relevant theory and empirical work; problem statement	Yes, page 3
S4	Purpose or research question	Purpose of the study and specific objectives or questions	Yes, page 3
	<b>Methods</b>		
S5	Qualitative approach and research paradigm	Qualitative approach (e.g., ethnography, grounded theory, case study, phenomenology, narrative research) and guiding theory if appropriate; identifying	Yes, page 3-4

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

		the research paradigm (e.g., postpositivist, constructivist/interpretivist) is also recommended; rationale	
S6	Researcher characteristics and reflexivity	Researchers' characteristics that may influence the research, including personal attributes, qualifications/experience, relationship with participants, assumptions, and/or presuppositions; potential or actual interaction between researchers' characteristics and the research questions, approach, methods, results, and/or transferability	Yes, page 4
S7	Context	Setting/site and salient contextual factors; rationale	Yes, page 4
S8	Sampling strategy	How and why research participants, documents, or events were selected; criteria for deciding when no further sampling was necessary (e.g., sampling saturation); rationale	Yes, page 4
S9	Ethical issues pertaining to human subjects	Documentation of approval by an appropriate ethics review board and participant consent, or explanation for lack thereof; other confidentiality and data security issues	Yes, page 4
S10	Data collection methods	Types of data collected; details of data collection procedures including (as appropriate) start and stop dates of data collection and analysis, iterative process, triangulation of sources/methods, and modification of procedures in response to evolving study findings; rationale	Yes, page 4-5, table 1
S11	Data collection instruments and technologies	Description of instruments (e.g., interview guides, questionnaires) and devices (e.g., audio recorders) used for data collection; if/how the instrument(s) changed over the course of the study	Yes, page 4-5, table 1
S12	Units of study	Number and relevant characteristics of participants, documents, or events included in the study; level of participation (could be reported in results)	Yes, page 4-8-, table 3
S13	Data processing	Methods for processing data prior to and during analysis, including transcription, data entry, data management and security, verification of data integrity, data coding, and anonymization/deidentification of excerpts	Yes, page 4-5
S14	Data analysis	Process by which inferences, themes, etc., were identified and developed, including the researchers involved in data analysis; usually references a specific paradigm or approach; rationale	Yes, page 5
S15	Techniques to enhance trustworthiness	Techniques to enhance trustworthiness and credibility of data analysis (e.g., member checking, audit trail, triangulation); rationale	Yes, page 4-5, table 2



	<b>Results/Findings</b>		
S16	Synthesis and interpretation	Main findings (e.g., interpretations, inferences, and themes); might include development of a theory or model, or integration with prior research or theory	Yes, page 5-8
S17	Links to empirical data	Evidence (e.g., quotes, field notes, text excerpts, photographs) to substantiate analytic findings	Yes, page 5-8
	<b>Discussion</b>		
S18	Integration with prior work, implications, transferability, and contribution(s) to the field	Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/ generalizability; identification of unique contribution(s) to scholarship in a discipline or field	Yes, page 9-10
S19	Limitations	Trustworthiness and limitations of findings	Yes, page 10
	<b>Other</b>		
S20	Conflicts of interest	Potential sources of influence or perceived influence on study conduct and conclusions; how these were managed	Yes, described at manuscript
S21	Funding	Sources of funding and other support; role of funders in data collection, interpretation, and reporting	Yes, described at manuscript